vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and PCB BANCORP (PCB). Click either name above to swap in a different company.
PCB BANCORP is the larger business by last-quarter revenue ($29.2M vs $19.1M, roughly 1.5× NewAmsterdam Pharma Co N.V.). On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 11.3%). PCB BANCORP produced more free cash flow last quarter ($24.4M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
NAMS vs PCB — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $29.2M |
| Net Profit | $-17.4M | — |
| Gross Margin | — | — |
| Operating Margin | -186.1% | 45.0% |
| Net Margin | -90.7% | — |
| Revenue YoY | 740.1% | 11.3% |
| Net Profit YoY | 55.5% | — |
| EPS (diluted) | $-0.15 | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $29.2M | ||
| Q3 25 | — | $30.4M | ||
| Q2 25 | $19.1M | $29.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $12.8M | $26.2M | ||
| Q3 24 | $29.1M | $25.3M | ||
| Q2 24 | — | $24.2M | ||
| Q1 24 | — | $23.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | $11.4M | ||
| Q2 25 | $-17.4M | $9.1M | ||
| Q1 25 | — | $7.7M | ||
| Q4 24 | $-92.2M | — | ||
| Q3 24 | $-16.6M | $7.8M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $4.7M |
| Q4 25 | — | 45.0% | ||
| Q3 25 | — | 52.3% | ||
| Q2 25 | -186.1% | 43.3% | ||
| Q1 25 | — | 40.2% | ||
| Q4 24 | -338.5% | 39.3% | ||
| Q3 24 | -85.9% | 42.2% | ||
| Q2 24 | — | 36.3% | ||
| Q1 24 | — | 27.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 37.5% | ||
| Q2 25 | -90.7% | 31.0% | ||
| Q1 25 | — | 28.8% | ||
| Q4 24 | -721.7% | — | ||
| Q3 24 | -57.2% | 30.8% | ||
| Q2 24 | — | 25.9% | ||
| Q1 24 | — | 19.6% |
| Q4 25 | — | $0.65 | ||
| Q3 25 | — | $0.78 | ||
| Q2 25 | $-0.15 | $0.62 | ||
| Q1 25 | — | $0.53 | ||
| Q4 24 | $-0.91 | $0.46 | ||
| Q3 24 | $-0.18 | $0.52 | ||
| Q2 24 | — | $0.43 | ||
| Q1 24 | — | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $207.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $390.0M |
| Total Assets | $815.1M | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $207.1M | ||
| Q3 25 | — | $369.5M | ||
| Q2 25 | $739.2M | $263.6M | ||
| Q1 25 | — | $214.3M | ||
| Q4 24 | $834.2M | $198.8M | ||
| Q3 24 | $422.7M | $193.1M | ||
| Q2 24 | — | $177.6M | ||
| Q1 24 | — | $239.8M |
| Q4 25 | — | $390.0M | ||
| Q3 25 | — | $384.5M | ||
| Q2 25 | $778.5M | $376.5M | ||
| Q1 25 | — | $370.9M | ||
| Q4 24 | $757.5M | $363.8M | ||
| Q3 24 | $378.9M | $362.3M | ||
| Q2 24 | — | $353.5M | ||
| Q1 24 | — | $350.0M |
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | $815.1M | $3.3B | ||
| Q1 25 | — | $3.2B | ||
| Q4 24 | $864.6M | $3.1B | ||
| Q3 24 | $439.2M | $2.9B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $2.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $26.6M |
| Free Cash FlowOCF − Capex | $-37.8M | $24.4M |
| FCF MarginFCF / Revenue | -197.2% | 83.6% |
| Capex IntensityCapex / Revenue | 0.5% | 7.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $46.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.6M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $-37.7M | $4.9M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $-37.5M | $39.0M | ||
| Q3 24 | $-12.5M | $11.9M | ||
| Q2 24 | — | $14.6M | ||
| Q1 24 | — | $8.2M |
| Q4 25 | — | $24.4M | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | $-37.8M | $3.8M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | $-37.5M | $34.9M | ||
| Q3 24 | $-12.6M | $11.9M | ||
| Q2 24 | — | $12.8M | ||
| Q1 24 | — | $6.0M |
| Q4 25 | — | 83.6% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | -197.2% | 13.1% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | -293.5% | 133.2% | ||
| Q3 24 | -43.2% | 46.8% | ||
| Q2 24 | — | 53.1% | ||
| Q1 24 | — | 25.2% |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.5% | 3.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | 0.0% | 15.5% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | — | 7.3% | ||
| Q1 24 | — | 9.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | — | 2.33× | ||
| Q1 24 | — | 1.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
